News
-
-
-
PRESS RELEASE
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
Psycheceutical Bioscience, Inc. appoints Neilank K. Jha, MD, as Executive Chairman and CEO to lead a turnaround, shifting focus from the psychedelic space to Brain-Computer Interface (BCI) technology. The company's mission is to develop products to improve the quality of life and survival rate of patients with neurological conditions. With partnerships with top-tier academic institutions and a prototype smart medical device in development, the company aims to revolutionize neurological therapies. The Board is exploring options to cure regulatory filing deficiencies and enable future corporate actions. NeuraSeed BCI, the next-generation neuroscience company, is focused on deep-brain implantation technology and brain-computer interfaces, aiming to transform neurological therapies for global benefit. -
-
-
-
-
-
Buildout, Inc. Unveils Game-Changing Technology Stack including an AI-Enabled Mobile App
-
Heal and Find Hope After a Friendship Breakup in When Best Friends Aren't Forever by Kristen Reed, Out Now
-
Viking Capital Announces Closing of Latest 268 Acquisition in Atlanta
-
Aflac: 6 Common Myths About Supplemental Insurance
-
Gabriel Resources Ltd. Initial Closing of Private Placement
-
Dalata Hotel Group PLC: HOL-Holding(s) in Company*
-
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
-
M&G Credit Income Investment Trust plc: Net Asset Value(s)
-
Funding Circle Plc: POS-Transaction in Own Shares
-
Explore Copenhagen's Culinary Gem: Khun Juk Oriental, Winner of the 2023 Thai Select Signature Award and Esteemed Taittinger Ambassador
-
VOGO : French National Handball League chooses VOGO to referee the French men’s championship (“Liqui Moly Starligue”).
-
ENGIE Q1 2024 Financial Information
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
Covivio Hotels successfully priced a €500 million 9-year Green Bond
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2024